Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Linsitinib (Anti-IGF-1R/IR) in Patients With Relapsed and/or Refractory Ewing Sarcoma

NCT02546544 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT02546544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02546544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Linsitinib (Anti-IGF-1R/IR) in Patients With Relapsed and/or Refractory Ewing Sarcoma
Lead sponsor
University of Oxford
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2014
Completion date
July 15, 2016
Enrollment
16 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

refractory ewing sarcoma, relapsed ewing sarcoma